This is a CEO appointment at an early-stage structural heart company developing a differentiated heart valve technology with broader platform potential.

Haga clic en "Solicitar" a continuación para enviar su candidatura. Asegúrese de que su CV está actualizado y de que ha leído primero las especificaciones del puesto.

The company has completed its seed financing, is backed by investors with both commercial and mission-driven objectives, and is building toward a Series A within 18–24 months. The lead programme is progressing through pre-clinical development toward first-in-human preparation.

What the company needs now is a leader to refine a multi-year company road map, build the organisation around it, secure the next round of capital, and lead the product into clinical development.

What You Will Do

Capital and Investor Leadership

- - Own and execute the Series A fundraise, working alongside the existing team, board, and advisors

- Build credibility with institutional healthcare investors, and construct the equity story that supports the raise

- Operate with capital discipline and with an “owner’s mindset” as a leader and shareholder in the company

Product and Clinical Progression
- - Drive the product through animal studies (current financing), first-in-human preparation, and early clinical studies (future financing)

- Develop clinical and regulatory strategy across both established and non-standard pathways relevant to the target markets

- Work closely with the technical advisory board to translate the technology into a commercially viable product

- Define the longer-term platform roadmap beyond the lead indication

Organisation Building
- - Build the personnel plan, and then the team and functions required to support clinical and regulatory progression

- Establish the culture,



cadence and standards of a company moving from research to clinical execution

Market and Stakeholder Engagement
- - Build credibility and relationships with cardiac surgeons, clinical advisors and key opinion leaders

- Represent the company to investors, clinicians, regulators and strategic partners, globally

- Work closely with the existing leadership and board to ensure an effective transition of executive responsibility.

What Success Looks Like

Within the first 24 months, the incoming CEO will have:

- - Closed a Series A on terms that support the business through to first-in-human

- Managed the team through completion of animal studies and established a clear, funded pathway into a first-in-human study

- Built a chronological organisation plan with the functions required for clinical progression

- Established the company as a credible name among cardiac surgeons and the structural heart community

- Maintained the capital discipline that has characterised the business to date

- Work closely with the team to maintain and build on a culture of success

The Adecuado Candidate
- - Startup operating experience. Senior operating responsibility within an early-stage medical device company, with a track record of delivering meaningful development milestones. First-time CEOs may be considered where startup operating experience is strong, and the individual is credible with the next-round funder.

- Fundraising capability. Demonstrable experience raising institutional capital,



or significant exposure to the process, with credibility among healthcare investors.

- Pre-clinical to first-in-human. Direct experience navigating a medical device from animal studies through regulatory strategy and into a first-in-human study

- Cardiac surgery understanding. A background in cardiac surgical devices or procedures, or deep familiarity with how cardiac surgeons evaluate and adopt new technology, is strongly preferred.

- Regulatory breadth. xugodme Experience developing regulatory strategies across international markets, with the judgement to navigate pathways beyond conventional FDA and CE Mark routes.

- Heart valve or wider structural heart background
- An established network across the structural heart clinical and investor community

The Right Mindset
- - Substance over style – the board values evidence and clear thinking over presentation

- Low ego but decisive – able to draw on the experience already around the table, absorb robust technical challenge, and then drive execution

- Personally resourceful; comfortable building with limited resources and operating in a start-up environment

- Committed to both the mission and the commercial opportunity

Why This Role
- - The first dedicated CEO seat at a company with a genuinely differentiated technology and a defined route to the clinic
- A board and advisory group with deep, directly relevant heart valve experience

- Investor backing that combines commercial ambition with a long-term, mission-driven view and strong advisory expert network
- A technology with the potential to change outcomes for a population that every existing option currently fails

- Meaningful equity participation and direct influence over the trajectory of the business

📌 Chief Executive Officer (España)
🏢 Synova Partners
📍 España